Endorsed resource - Paediatric Musculoskeletal Matters (PMM)
Newcastle University has produced a learning resource that supports clinical assessment recommendations in the NICE guidelines on suspected cancer and child maltreatment. In addition it also supports the NICE technology appraisal guidance on abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis and tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
Disclaimer
Endorsed resources are complementary information not produced by NICE. This resource has been developed by Newcastle University and is not maintained by NICE. NICE has not made any judgement about the quality and usability of the resource. In the event of any issues or errors, please contact the resource developer.
This page was last updated: